A big thank you to everyone who joined our webinar yesterday! Together with Fiona Jeganathan Head of Pharmacology and Screening at the Alzheimer's Research UK UCL Drug Discovery Institute, we showed how CETSA® technology is transforming lead generation by delivering novel modulators like PLCγ2. The session shed light on how CETSA helps confirm compound-target engagement, paving the way for breakthroughs in potential treatments for Alzheimer’s disease. Your participation and insightful questions were invaluable! For those who missed it, stay tuned as we’ll soon share key highlights and insights from the event. #drugdiscovery #CETSA #targetengagement #Webinar
Om oss
At Pelago Bioscience, we’re here to help you make faster, better-informed decisions in drug discovery. In 2010, our founders began to develop our proprietary CETSA® (Cellular Thermal Shift Assay) technology, publishing a seminal research paper in Science 2013. Since then, Pelago Bioscience has become the leading CRO providing actionable, biologically relevant insights at the pre-clinical stage.Unlike traditional methods, CETSA gives you a reliable picture of drug-target interactions, ensuring that what you see in cells translates to patients. Our services rest on four pillars: • Certainty in Biological Relevance: CETSA’s physiological approach helps minimize late-stage risks. • Fast & Early Confidence: We deliver actionable insights in just 10 days-10 weeks (service dependent), eliminating unnecessary complexities so you can make decisions faster. • Insights & Progress: Our data supports compound prioritization and predicts future research steps, reducing project costs. • Extended Team Support: We work as your dedicated partner, designing fit-for-purpose studies that align with your goals. With Pelago Bioscience, you gain more than just data; you gain a trusted partner in your discovery journey.
- Webbplats
-
http://www.pelagobio.com
Extern länk för Pelago Bioscience AB
- Bransch
- Forskning inom bioteknik
- Företagsstorlek
- 51–200 anställda
- Huvudkontor
- Solna
- Typ
- Privatägt företag
- Grundat
- 2013
- Specialistområden
- Target Engagement, Drug Discovery, Fee for Service, Sub licensing, Translational Science, Biomarkers, CETSA, Selectivity och Assay Development
Adresser
-
Primär
Få vägbeskrivning
Pelago Bioscience AB
Scheeles väg 1
Solna, 17165, SE
Anställda på Pelago Bioscience AB
Uppdateringar
-
Last chance to register for our December 4th webinar. Together with the Alzheimer's Research Drug Discovery Unit, University College of London we’re happy to invite you to a webinar on how CETSA® has been used to deliver novel modulators for potential new treatment of Alzheimer's disease. 📅 Date: December 4 🕓 Time: 17:00 CET | 16:00 GMT | 11:00 EST | 08:00 PST Register here: https://hubs.la/Q02-87kg0 #LeadGeneration #Webinar #Pharmacology #DrugDiscovery #LifeSciences
-
-
We’re honored to be nominated for the SwedenBIO Award! Pelago Bioscience AB is one of the three finalists for the SwedenBIO Award! We are incredibly proud of our work in advancing the field of drug discovery with our patented CETSA® (Cellular Thermal Shift Assay) technology. A huge thank you to SwedenBIO and HealthCap for this recognition, and congratulations to all the finalists! We look forward to the SwedenBIO Summit on December 11th, where the winner will be announced. 🏆 #DrugDiscovery #CETSA #lifescience
We have three finalists for the SwedenBIO Award! 🥁 Pelago Bioscience AB is providing its patented CETSA® (Cellular Thermal Shift Assay) technology to the global pharmaceutical industry. The technology enables direct measurement of target engagement in living cells. This innovative approach accelerates the development of effective and safe therapeutics. Xbrane Biopharma AB Biopharma is focused on developing and manufacturing biosimilars with a proprietary platform technology, which enables a cost-efficient production of biologics. The pipeline consists of projects within ophthalmology and oncology with Ximluci® now being approved in the EU. Vicore Pharma AB is developing treatments for rare lung diseases and fibrotic conditions, targeting the angiotensin II type 2 receptor (AT2R) to combat inflammation and fibrosis. Vicore’s lead candidate, C21, now in Ph II, aims to address severe unmet medical needs in pulmonary and systemic fibrosis. The winner will be announced at SwedenBIO Summit on the 11th December. The SwedenBIO Award is presented in cooperation with HealthCap. Reminder – registration for Summit is open until December 3. 𝗩𝗲𝗻𝘂𝗲: Grand Hôtel, Stockholm 𝗧𝗶𝗺𝗲 & 𝗱𝗮𝘁𝗲: December 11th 13.00 Curious about the program or want to register? Take a look here: https://lnkd.in/dzshJRwn
-
-
Have you heard about our December 4th webinar? Together with the Alzheimer's Research UK UCL Drug Discovery Institute, we’re happy to invite you to a webinar on how CETSA® has been used to deliver novel modulators for potential new treatment of Alzheimer's disease. How CETSA has been applied in Lead Generation delivering novel modulators of PLCγ2 📅 Date: December 4 🕓 Time: 17:00 CET | 16:00 GMT | 11:00 EST | 08:00 PST 🎙️ Fiona Jeganathan Register here: https://hubs.la/Q02ZGTJw0 #LeadGeneration #Webinar #Pharmacology #DrugDiscovery #LifeSciences
-
-
Join us for an exclusive webinar with Alzheimer's Research UK UCL Drug Discovery Institute. Discover how CETSA® is helping experts to confirm compound-target engagement. Gain insights from Fiona Jeganathan, Head of Pharmacology and Screening at Alzheimer's Research UK UCL Drug Discovery Institute. 📅 Date: December 4 🕓 Time: 17:00 CET | 16:00 GMT | 11:00 EST | 08:00 PST Register here: https://hubs.la/Q02Xj4wj0 #LeadGeneration #Webinar #Pharmacology #DrugDiscovery #LifeSciences
-
-
Today we had the pleasure of welcoming the CEO of Umlaut.bio GmbH Karsten Fischer, to the home of CETSA®. We're looking forward to working together with him and the Umlaut Bio team to help them reach their drug discovery goals. "We are thrilled that Umlaut has chosen to partner with us in their Drug Discovery efforts. Their focus on the development of small molecules targeting modified tRNA nucleotides aligns perfectly with our expertise and we're excited to support them in achieving their goals. We're happy they've chosen us as a trusted partner in their efforts and we look forward to a close and successful collaboration." Michael Dabrowski, CEO, Pelago Bioscience AB "We are working on novel exciting targets and were looking for an assay which is measuring target engagement in a cellular environment under physiological conditions. With this, CETSA as screening assay was the logical choice for us and we are looking forward to working together with Pelago Bioscience during our drug discovery journey." Karsten Fischer, CEO, Umlaut.bio GmbH #businesspartnership #drugdiscovery #trustedpartner #partnership
-
-
We are attending Europe's largest partnering event, BIO-Europe 2024 as a part of Sweden’s vibrant life science ecosystem. Our CEO, Michael Dabrowski, along with Senior Regional Sales Manager Marianne Alksnis and Head of Sales Magnus Lejelöv, will be at the Swedish Pavilion and look forward to meeting you. Come say hello and discover we can help you gain early confidence in your drug discovery projects. After a day at BIO-Europe, we invite you to keep the conversation going at our nearby facility. Enjoy a guided tour of our lab, explore the latest developments at the Home of CETSA®, and connect with industry peers over refreshments. Check out event highlights and RSVP for our Open House on our website: https://hubs.la/Q02WgyqC0 #SwedenBio #DrugDiscovery #BioEurope2024
-
-
Will you be attending the 7th Annual TPD & Induced Proximity Summit 2024 in Boston, MA, from October 28-31? 💡Visit us at Booth 9 to meet our team: Brian W. J., Stephen Kosteski and Michael Dabrowski. Discover how our services can bring certainty to your drug discovery projects. CETSA® (Cellular Thermal Shift Assay) is an effective method for studying interactions between small molecules and their protein targets, particularly useful in targeted protein degradation (TPD) as it improves insights from degradation profiles. CETSA can be conducted in cell lysates and intact cells without modifying compounds, proteins, or cellular environments. 👀 Don't miss our poster presentation and discover why CETSA is key to elucidate the connections between molecular dynamics and cellular effects. 🖼️ Poster Session 19 📅 29 October 🕛 3:00 PM 🔗 Unlock deeper insights into biological relevance: https://hubs.la/Q02VGPp-0 #TPD2024 #proteins #drugdiscovery #degradation
-
-
We are approaching the end of an exciting and inspiring HUPO2024 meeting in Dresden. CETSA® with MS detection (TPP or PISA) does not need any introduction to this crowd. Lots of data and attention at seminars and only today there are more than a dozen posters where our method has been instrumental. One of these posters titled "Igniting Drug Discovery - pushing CETSA-MS to scale” summarize some of the nice work carried out by one of our licensees, Bayer here represented by Jana Flegel and Shiva Ahmadi from the Wuppertal site. #HUPO #HUPO2024 #drugdiscovery
-
-
We’re excited to share that Daniel Martinez Molina and Alexey Chernobrovkin will be heading to the Human Proteome Organization (HUPO) World Congress in Dresden from October 20-24! 🧬✨ Even more exciting – Alexey will be giving a talk at a lunch seminar sponsored by Thermo Fisher. 🗓️ Monday, 21 October, 2024 🕛 12:15 – 13:15 CEST 📍 International Congress Center Dresden – Conference room 5+6 🎤 Title: Boosting throughput of thermal proteome profiling Thermo Fisher has been a fantastic partner, and we’re excited to share how we’re using the Orbitrap Astral mass-spectrometer in our daily work. If you're going to be at HUPO, definitely swing by and check out Alexey's session. It’s a great chance to see the tech in action and chat with us. Hope to see you there! #HUPO2024 #MassSpec #Proteomics #ThermoFisher #ScienceInAction
-